Drug Approval | March 09, 2024
USFDA conducts inspection at Alembic Pharmaceuticals' Panelav oncology formulation facility
The company will provide comprehensive response to USFDA for the observations
The company will provide comprehensive response to USFDA for the observations
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
ANVISA issues CGMP to Concord Biotech’s Unit I
Acquisition of exclusive commercialization rights for European markets
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
The product will be launched in March 2024
Eugia Pharma Specialities restarts production at terminally sterilized product lines
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
The observations do not pose any risk to site's compliance standards or its business continuity
Subscribe To Our Newsletter & Stay Updated
